Related Experiment Video
Updated: May 27, 2026
09:46
Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
Current therapies in primary immune thrombocytopenia
1Section of Hematology Oncology, Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut 06520, USA. salley.pels@yale.edu
Seminars in Thrombosis and Hemostasis
|November 22, 2011
Summary
Immune thrombocytopenia (ITP) is an autoimmune disorder causing platelet destruction. New therapies, including thrombopoietic agents, enhance platelet production, offering new treatment options for severe ITP.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Immune thrombocytopenia (ITP) is an autoimmune condition characterized by antibody-mediated platelet destruction.
- Traditional therapies focus on reducing antibody production or platelet destruction via the reticuloendothelial system.
Purpose of the Study:
- To review commonly used therapeutic agents for severe thrombocytopenia in immune thrombocytopenia (ITP).
- To highlight newer therapeutic strategies, including thrombopoietic agents, for managing ITP.
Main Methods:
- This is a review article, synthesizing information on ITP therapies.
- It covers established treatments like steroids, immunoglobulin, splenectomy, and rituximab.
- It also discusses emerging therapies such as thrombopoietic agents.
Main Results:
- Established therapies aim to suppress the immune system or remove the spleen.
- Newer agents focus on stimulating platelet production to counteract destruction.
- A range of treatment options are available for both newly diagnosed and chronic ITP.
Conclusions:
- Understanding ITP pathophysiology has led to diverse therapeutic approaches.
- Thrombopoietic agents represent a significant advancement in managing ITP by boosting platelet counts.
- The review provides an overview of current and emerging treatments for severe ITP.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...